ROIV Overview

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Roivant Sciences Ltd revenue for the last quarter amounts to 2.00M USD, decreased -77.83

Roivant Sciences Ltd. EPS for the last quarter amounts to -0.38 USD, decreased -265.22

Roivant Sciences Ltd (ROIV) has 750 emplpoyees as of April 01 2026.

Today ROIV has the market capitalization of 19.82B USD.